1030419-85-2

Upstream product

• 105-13-5 4-Methoxybenzyl alcohol 
• 943-88-4 4-(p-methoxyphenyl)-3-butene-2-one 
• 123-11-5 4-methoxy-benzaldehyde 
• 1774-12-5 5-(4-methoxyphenyl)-1,3-cyclohexanedione 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 

Downstream Products

• 1174555-36-2 C₅H₁₁N*C₂₅H₁₉N₃O₅S 
• 1031967-94-8 C₂₇H₂₄N₂O₃S 

Relevant academic research and scientific papers

One-pot Synthesis of Benzo[4,5]imidazo[1,2-a]pyridine Derivatives in Aqueous Conditions

One-pot reaction of cyclic 1,3-diketones, dimethylformamide dimethylacetal (DMFDMA) and 2-(1H-benzo[d]imidaz-2-yl)acetonitrile was found to be a highly selective process leading to 4-oxo-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]quinolin-6-yl cyanides. Op

Inhibition of Autophagy by a Small Molecule through Covalent Modification of the LC3 Protein

The autophagic ubiquitin-like protein LC3 functions through interactions with LC3-interaction regions (LIRs) of other autophagy proteins, including autophagy receptors, which stands out as a promising protein–protein interaction (PPI) target for the intervention of autophagy. Post-translational modifications like acetylation of Lys49 on the LIR-interacting surface could disrupt the interaction, offering an opportunity to design covalent small molecules interfering with the interface. Through screening covalent compounds, we discovered a small molecule modulator of LC3A/B that covalently modifies LC3A/B protein at Lys49. Activity-based protein profiling (ABPP) based evaluations reveal that a derivative molecule DC-LC3in-D5 exhibits a potent covalent reactivity and selectivity to LC3A/B in HeLa cells. DC-LC3in-D5 compromises LC3B lipidation in vitro and in HeLa cells, leading to deficiency in the formation of autophagic structures and autophagic substrate degradation. DC-LC3in-D5 could serve as a powerful tool for autophagy research as well as for therapeutic interventions.

Tetrahydroquinazoline derivatives and pharmaceutical composition for preventing or treating psoriasis comprising the same

The present invention relates to a tetrahydroquinazoline derivative and a pharmaceutical composition for preventing or treating psoriasis containing the same as an active ingredient. The compound provided in one aspect of the present invention has an effe

Synthesis of novel 3-(1,3-thiazol-2-yl)-7,8-dihydroquinoline-2,5(1H,6H)- diones

An efficient method for the synthesis of novel 3-(1,3-thiazol-2-yl)-7,8- dihydroquinoline-2,5(1H,6H)-diones from various 2- dimethylaminomethylidenecyclohexane-1,3-diones, (1,3-thiazol-2-yl)acetonitriles, and dimethylformamide dimethyl acetal was developed. These transformations proceeded through intermediate 2-[2-(4-aryl-1,3-thiazol-2-yl)-2-cyanoethenyl]-3- oxocyclohex-1-en-1-olates. They were isolated as piperidinium salts and used in further heterocyclization reactions with aromatic amines, giving novel 1-aryl-3-(1,3-thiazol-2-yl)-7,8-dihydroquinoline-2,5(1H,6H)-diones. These compounds were also obtained by preparative three-step "one pot" synthesis under controlled microwave irradiation.